FORBES-TATE

Lobbying for CSL BEHRING · Biopharmaceutical Company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Pennsylvania · House · Senate · $60,000.00 income · posted Apr 16, 2025

Lobbying activity 2

Medical/Disease Research/Clinical Labs

Issues related to biopharmaceutical pricing; Issues related to plasma and plasma derived therapies; Issues related to the Preserving Life-saving Access to Specialty Medicines in America Act.

Medicare/Medicaid

Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to biopharmaceutical pricing; Issues related to plasma and plasma derived therapies; Issues related to the Preserving Life-saving Access to Specialty Medicines in America Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.